McMinn Rachel has filed 7 insider transactions across 1 company since March 2024.
Most recent transaction: a sale of 3352 shares of Neurogene Inc. ($NGNE) on March 26, 2026.
Activity breakdown: 1 open-market purchase and 1 sale.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 26, 2026 | Neurogene Inc. | $NGNE | McMinn Rachel | Chief Executive Officer | S | Common Stock | 3352 | $22.07 | 1,344,307.0000 | 21,168,431 | 0.25% | 0.02% |
| Feb. 20, 2026 | Neurogene Inc. | $NGNE | McMinn Rachel | Chief Executive Officer | A | Common Stock | 25900 | $0.00 | 1,347,659.0000 | 21,168,431 | 1.96% | 0.12% |
| Feb. 20, 2026 | Neurogene Inc. | $NGNE | McMinn Rachel | Chief Executive Officer | A | Stock Option (Right to Buy) | 155100 | $0.00 | 155,100.0000 | 21,168,431 | 9999.99% | 0.73% |
| March 26, 2025 | Neurogene Inc. | $NGNE | McMinn Rachel | Chief Executive Officer | A | Employee Stock Option (Right to buy) | 143500 | $0.00 | 143,500.0000 | 17,567,082 | 9999.99% | 0.82% |
| March 26, 2025 | Neurogene Inc. | $NGNE | McMinn Rachel | Chief Executive Officer | A | Common Stock | 23900 | $0.00 | 1,274,259.0000 | 17,567,082 | 1.91% | 0.14% |
| Nov. 22, 2024 | Neurogene Inc. | $NGNE | McMinn Rachel | Chief Executive Officer | P | Common Stock | 47500 | $20.40 | 1,297,859.0000 | 16,953,443 | 3.80% | 0.28% |
| March 13, 2024 | Neurogene Inc. | $NGNE | McMinn Rachel | Chief Executive Officer | A | Employee Stock Option (Right to buy) | 93282 | $0.00 | 93,282.0000 | 4,656,947 | 9999.99% | 2.00% |